Ke Liu

Ke Liu has a wealth of experience in the field of cancer biology. Ke began their career in 2007 as a Postdoctoral Fellow at the National Center for Advancing Translational Sciences (NCATS), where they designed, developed, and optimized biochemical and cell-based assays for high-throughput screening (HTS). Ke also conducted secondary screening and functional studies on selected lead series for hit/lead identification and structure activity relationship (SAR) optimization efforts.

In 2010, Ke Liu moved to the Broad Institute of MIT and Harvard, where they worked as a Research Scientist I and II. During their time there, they purified proteins from E. coli and mammalian cells for HTS, and analytically characterized purified proteins using various biochemical and biophysical approaches. Ke also characterized enzyme kinetics and protein-protein interactions, and developed biochemical and cell-based assays for HTS or functional studies.

In 2014, Ke Liu joined Incyte, where they worked as a Senior Research Investigator and Research Investigator. Finally, in 2018, they joined NiKang Therapeutics Inc. as the Director of Cancer Biology and Sr Principal Investigator.

Ke Liu obtained a PhD in Molecular and Cell Biology from Vanderbilt University and a Bachelor's Degree from the University of Science and Technology of China.